Spider Silk, Splicing & Strategic Capital: Biotech and Innovation Dominate the Morning Tape

September 25, 2025

DENVER, Colo., Sep 25, 2025 (247marketnews.com)- Wall Street opens today with biotech breakthroughs, industrial innovation, and major institutional deals setting the tone. Let’s dive into the names making headlines this morning and worth watching into the open and beyond.

Kraig Biocraft Laboratories (OTCQB:KBLB) just completed its first simultaneous dual-facility production cycle, a key operational win for its plan to commercialize high-performance recombinant spider silk. By staggering production schedules across two independent rearing centers, the company has established a continuous, scalable output model that eliminates downtime and builds supply chain resilience. CEO Kim Thompson called it a “transformative step,” emphasizing how it validates their industrial-scale spider silk platform. This move lays the foundation for a broader ramp-up in Q4 and positions KBLB as a niche manufacturing innovator in commercially viable high-performance biomaterials.

PepGen (NASDAQ:PEPG) is surging after reporting record-breaking clinical results for its lead candidate, PGN-EDODM1, in patients with myotonic dystrophy type 1. In its FREEDOM Phase 1 trial, a single 15 mg/kg dose led to 53.7% mean splicing correction, the highest ever reported in humans with DM1. All patients responded positively, and the drug was well-tolerated, with only mild or moderate AEs. To capitalize on momentum, PepGen also priced a $100 million public offering at $3.20/share to fund further development. These dual catalysts put PEPG squarely in the spotlight among neuromuscular therapy plays.

Immuneering (NASDAQ:IMRX) is grabbing headlines after pricing a $175 million public offering of common stock at $9.23/share, its last closing price. Additionally, Sanofi (NASDAQ:SNY) is participating in a $25 million private placement, underscoring institutional belief in Immuneering’s oncology platform. Proceeds will accelerate clinical development and expand its cancer drug pipeline. With over $200 million in fresh capital expected to hit the books, IMRX is now a fully funded story in a space that’s heating up.

Plus Therapeutics (NASDAQ:PSTV) subsidiary CNSide Diagnostics just scored a nationwide coverage agreement with UnitedHealthcare (NYSE:UNH). Effective September 15, this partnership brings CNSide’s cerebrospinal fluid (CSF) tumor cell enumeration test under coverage for over 51 million Americans. The test, used for leptomeningeal metastases, has shown 92% sensitivity and 95% specificity, and influenced treatment decisions in 90% of cases across 120+ U.S. cancer centers. This milestone could boost revenue visibility and adoption for PSTV in a high-impact oncology niche.

PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 247 is a third-party media provider and has been compensated by one or more featured companies for providing ongoing KBLB market outreach and other services.. This press release may include technical analysis and should not be construed as financial or investment advice. Trading stocks involves risks, and readers should consult with their financial advisor before making investment decisions. Please review 247’s Full Disclaimer https://www.247marketnews.com/disclaimer/. Please go to https://247marketnews.com/kblb-disclosure/ for further KBLB and 247marketnews.com disclosure information.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (KBLB, PPEG, IMRX, SNY, PSTV, UNH)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.